Massive Bio's recent certification underscores its commitment to integrating AI in healthcare, particularly in precision oncology and health data infrastructure.

Massive Bio operates across 17 countries and collaborates with pharmaceutical companies and research organizations, having been recognized by the National Cancer Institute as a founding member of the CancerX partnership.

Through its recent certification and strategic partnerships, Massive Bio is poised to significantly impact the healthcare landscape in France.

In this context, Massive Bio's certified platform plays a crucial role in bridging technology with patient impact, particularly in areas like precision oncology.

The company's AI-powered platform for clinical trial matching supports France's efforts to improve patient access to research opportunities.

The certification from the French Data Protection Authority (CNIL) confirms Massive Bio's compliance with GDPR and French data privacy laws, allowing hospitals to share medical records safely.

This certification enables hospitals and physicians to collaborate with Massive Bio for clinical trial matching without facing legal obstacles.

Mert Sari, Director of OUS Provider Engagement at Massive Bio, highlighted the company's commitment to expanding its presence in France and Europe through institutional partnerships.

The company is also a participant in the Cancer Moonshot initiative, further demonstrating its commitment to advancing cancer research and treatment.

As part of this initiative, the country is introducing mandatory AI training for healthcare students, which reflects its commitment to modernizing healthcare delivery.

France is making a significant investment of €109 billion in artificial intelligence in 2025, aiming to enhance its healthcare system and position itself as a leader in ethical medical innovation.

Founded by Selin Kurnaz, Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, Massive Bio aims to transform the pharmaceutical value chain using AI-driven solutions to streamline patient journeys and optimize clinical trials.